AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05925140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Therapy-enhanced Standard Care (CTSC)
Description: (1) Methylprednisone (120mg/24h/IV) followed by 80mg/day (7days), and if necessary, continued with 40mg/day; or a pulse therapy (patient in critical state (360mg/day/IV) for 3 serial days, followed by 80mg/day (7days), and if necessary, continued with a dose of 40mg/day. (2) Standard Care: Normal Saline 0.9% (500cc/24h); vitamins \[D (Oravil, 100.000IU/2ml PO STAT), C (10g/250cc in normal saline, 60drops/min/day), B (BECOZYME, 6 ampoules IV STAT)\]; Omeprazole (RISEK, 40 mg/day IV); Paracetamol (PREFALGAN, 1g IV each 8h 3 times per day), Ketoprofen (PROFENID, 100mg/12h); Ceftriaxone (ROCEPHIN, 2g/day for 3 consecutive days), Doxycycline (VIBRAMYCIN, 100mg/12h PO for 8 days), Ivermectin (12mg/day for a period of 5 days); TOPLEXIL (Syrup, 10cc/each 8h) or SINECOD (Syrup, 15cc/each 8h); ATORVASTATIN (20mg/day); LOVENOX (40mg/12h if \<80kg, or 60mg/12h if >80kg). Tranquillizers: NORMOCALM (400mg/night), XANAX (10mg/day), SEROQUEL (25mg/night), DEPIA (2mg/day), to be administered orally
Study NCT05206617 — intervention group
Intervention type: OTHER
Intervention: No intervention - pure observational study
Description: No intervention
Study NCT03582722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months.
Study NCT03582722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months.
Study NCT03582722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: A multivitamin will be provided to be taken once daily, at bedtime.
Study NCT03582722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin
Description: A multivitamin will be provided to be taken once daily, at bedtime.
Study NCT01188655 — intervention group
Intervention type: DRUG
Intervention: Enbrel
Description: The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits.
Study NCT04084132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary valve replacement
Description: Surgical implantation of an adult-sized (≥ 18 mm) homograft or Contegra graft as right ventricle-to-pulmonary artery conduit under cardiopulmonary bypass through a sternotomy.
Study NCT03493867 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vitaliti
Description: Measurements recorded by the Vitaliti device will be compared to the recordings from the arterial catheter.
Study NCT02263495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
Study NCT02263495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)
Study NCT02263495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
Study NCT02263495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
Study NCT03648307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood sample for Hb A1C and lipid profile, blood pressure and BMI
Study NCT03546790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Marijuana smoked via blunts with different cigar wrappers
Study NCT03428685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone Oral Tablet
Description: Oral dysdrogesteone 10mg tds will be prescribed from 12 - 36+6 weeks.
Study NCT03428685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebos will be prescribed from 12 - 36+6 weeks.
Study NCT03292952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP415 oral capsule
Description: Daily dose
Study NCT03292952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Daily dose
Study NCT03809832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological sampling
Description: An microbiological sampling of the ventilator humidifier will be performed.
Study NCT00034814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enzyme-inducing placebo TID
Study NCT00034814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: Enzyme-inducing Talampanel 35 mg TID
Study NCT03882554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoNS Treatment
Description: PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages
Study NCT03827369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ICU patient
Description: Our study is to measure the coefficient of variation of the HCV of the radial arterial pulse among ICU patients with multiple organ failures (MOF). Patients admitted to Taoyuan General Hospital were recorded during the 6 months study.
Study NCT00770536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3: AMG 386 15mg/kg + Liposomal doxorubicin
Description: A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
Study NCT00770536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1: AMG 386 10 mg/kg + Topotecan
Description: B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
Study NCT00770536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B3: AMG 386 15mg/kg + Topotecan
Description: AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
Study NCT05777161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Coached Exposure Therapy - Individualized
Description: Subject and parent begin by working with a therapist to create an individualized fear hierarchy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
Study NCT05777161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: Subjects will work with a therapist using anxiety management strategies to address thoughts, feelings, and behaviors.
Study NCT05777161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Coached Exposure Therapy - Group (removed from study)
Description: Subjects and parents will work in a group setting to receive exposure therapy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
Study NCT01520974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ProBiora3 mints
Description: Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria
Study NCT01520974 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
Study NCT02031016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
Study NCT02031016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
Study NCT02031016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
Study NCT01034787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
Study NCT02221037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2862277
Description: It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device.
Study NCT02221037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device.
Study NCT03141879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HUR equipment resistance training intervention
Description: Resistance training intervention
Study NCT02017730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986020
Study NCT02017730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]BMT-136088
Study NCT04934150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: navigated repetitive Transcranial Stimulation
Description: High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.
Study NCT04934150 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: navigated repetitive Transcranial Stimulation
Description: High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.
Study NCT03772431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female Voice
Description: The survey was narrated by a female voice
Study NCT03772431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Introduction
Description: The survey introduction was worded to include motivational content
Study NCT03772431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Male Voice
Description: The survey was narrated by a male voice
Study NCT03772431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Introduction
Description: The survey introduction was worded to include informational content
Study NCT03359824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Study NCT00004135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00004135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Study NCT00004135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00004135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00004135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT01299805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated tablet
Study NCT01299805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules.
Study NCT01363804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
Study NCT04564261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Healthy Relationship and Safety Planning Tool
Description: The app delivers evidence-based information and resources in three sections:~My Relationship: contains a series of activities (e.g., quizzes) to raise awareness of common myths about unhealthy relationships, determine characteristics of healthy relationships, examine the red flags in an unhealthy relationship, and assess risk factors for more severe abuse. Participants are provided with personalized messages about their relationship health and safety based on the answers they endorse.~My Strategies: personalized strategies to increase participants' safety and well-being based on responses in the previous section.~My Resources: direct links to the National Dating Abuse hotline, textline, and chatline, as well as personalized health and safety resources.
Study NCT03977831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Cystectomy
Description: Participants are randomly and blinded assigned
Study NCT00695435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOBRADEX Ophthalmic Suspension
Description: TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
Study NCT00695435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
Description: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
Study NCT00695435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOBREX Ophthalmic Solution
Description: TOBREX Ophthalmic Solution 1 drop each eye at baseline
Study NCT02170948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
Study NCT04297371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CMR examination
Description: After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
Study NCT00034814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: Enzyme-inducing TLP 50mg TID
Study NCT00034814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-enzyme-inducing placebo TID
Study NCT00034814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: Non-enzyme-inducing TLP 25mg TID
Study NCT02661841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LI-Guided Therapy
Description: Preemptive treatment according to LI monitoring
Study NCT02661841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart Failure Guidelines
Description: Treatment according to clinical signs
Study NCT02661841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure Guidelines
Description: Treatment according to clinical signs
Study NCT00817206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-Tacro
Description: LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.
Study NCT00817206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
Study NCT01700985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 122-0551
Description: Applied twice daily for two weeks
Study NCT03319576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding at 4 hours
Description: Patients will be fed 4 hours after their gastrostomy tube placement procedure.
Study NCT00057564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (Thalidomide + Dexamethasone)
Description: Thalidomide 50mg/day + Dexamethasone 40mg
Study NCT00057564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B (Placebo + Dexamethasone)
Description: Placebo + Dexamethasone 40mg
Study NCT03859076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB-BP
Description: MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions \& a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, \& specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, \& stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
Study NCT04564261 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Teen Relationship and Health Website
Description: The control group website will provide participants with tools to learn about health topics including examining healthy relationships. The resources will be targeted to adolescents. The control group website is not personalized to the participant or their relationship.
Study NCT03746652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab, Ixazomib, Dexamethasone
Description: Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg
Study NCT03699605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VESMP
Description: . The application contains following seven domains: spontaneous speech, comprehension, naming, reading, writing, imitation and automated speech. The programme was developed in Urdu language which contains different daily functional words, phrases and sentences. Treatment stimuli consisted of images of objects along with auditory sounds of person and actions cues. The voice output can operate by pressing the selected picture with index finger. Participants received 1-16 weeks of therapy using software of two domains with different difficulty levels. Specifically the programme included seven domains within the software comprising of eight 30-45 minutes sessions (4 days per week for total 16weeks). The measurement will be taken at 0 week (baseline) after 16 weeks.
Study NCT03699605 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapy
Description: , All subjects participated in an traditional therapy group in routine and received MIT for 4 months of periods with three sessions per week to improve language skills.
Study NCT03639519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 500Mg Chew Tab
Description: Ascorbic acid will be administered at the night before surgery and will be continued for five days
Study NCT04620902 — intervention group
Intervention type: OTHER
Intervention: Tear sampling
Description: Tear sampling using Schirmer's strips
Study NCT03859076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Control
Description: Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
Study NCT04792385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E4/DRSP 15/3 mg combined tablet
Description: One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.